4-羟基-2,5-二甲基苯甲酸甲酯 | 27023-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羟基-2,5-二甲基苯甲酸甲酯
• 英文名称: methyl 4-hydroxy-2,5-dimethylbenzoate
• 英文别名: methyl 2,5-dimethyl-4-hydroxybenzoate
• CAS: 27023-05-8
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: VZEFUBJGXCSOBD-UHFFFAOYSA-N

物化性质

• 熔点：
  114-118°C
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  4-羟基-2,5-二甲基苯甲酸甲酯 在 草酰氯 、 20% palladium hydroxide on carbon 、 四丁基氯化铵 、 氢气 、 potassium carbonate 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.33h， 生成 [1-(2,5-dimethyl-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl)-2-methyl-1H-indol-3-yl]acetic acid
  参考文献：
  名称：

  Discovery of selective indole-based prostaglandin D2 receptor antagonist

  摘要：

  A series of N-benzoyl-2-methylindole-3-acetic acids were synthesized and biologically evaluated as prostaglandin (PG) D-2 receptor antagonists. Some of the selected compounds significantly inhibited OVA-induced vascular permeability in guinea pig conjunctiva after oral dosing. Structure-activity relationship study is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.014
• 作为产物：
  描述：

  2,5-二甲基-4-甲氧基苯甲酸 在 氯化亚砜 、 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-羟基-2,5-二甲基苯甲酸甲酯
  参考文献：
  名称：

  3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE

  摘要：

  公开号：

  EP2471792B1

文献信息

• Computational and Experimental Studies of Phthaloyl Peroxide-Mediated Hydroxylation of Arenes Yield a More Reactive Derivative, 4,5-Dichlorophthaloyl Peroxide
  作者：Andrew M. Camelio、Yong Liang、Anders M. Eliasen、Trevor C. Johnson、Changxia Yuan、Alex W. Schuppe、K. N. Houk、Dionicio Siegel

  DOI：10.1021/acs.joc.5b01079

  日期：2015.8.21

  experimentally determined to possess enhanced reactivity, has expanded the scope of the reaction while maintaining a high level of tolerance for diverse functional groups. The reaction proceeds through a novel “reverse-rebound” mechanism with diradical intermediates. Mechanistic insight was achieved through isolation and characterization of minor byproducts, determination of linear free energy correlations, and

  用邻苯二甲酰过氧化试剂氧化芳烃提供了一种合成苯酚的新方法。通过计算预测并实验确定具有增强的反应性的新的，更具反应性的芳烃氧化剂4,5-二氯邻苯二甲酰过氧化物扩大了反应范围，同时保持了对各种官能团的高度耐受性。该反应通过具有双自由基中间体的新型“逆向反弹”机理进行。通过分离和表征次要副产物，确定线性自由能的相关性以及对芳烃的取代基效应进行计算分析，从而获得了机理上的见解，每一项都为通过双自由基途径进行的反应提供了额外的支持。
• Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof
  申请人：Kobayashi Junichi

  公开号：US20060128807A1

  公开（公告）日：2006-06-15

  The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R 1 and R 2 are each hydrogen or lower alkyl; R 3 , R 4 , R 5 and R 6 are each hydrogen, halogen, lower alkyl or lower alkoxy; R 7 and R 8 are each hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, cyano, a hydroxyl group, lower acyl, carboxy or the like; R 9 is —C(O)—R 10 , -A 1 -C(O)—R 10 , —O-A 2 -C(O)—R 10 or a tetrazol-5-yl group, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

  本发明提供一般式（I）所表示的化合物或其药学上可接受的盐，其中R1和R2均为氢或较低的烷基；R3、R4、R5和R6均为氢、卤素、较低的烷基或较低的烷氧基；R7和R8均为氢、卤素、较低的烷基、卤代较低的烷基、较低的烷氧基、环烷基、芳基、杂芳基、氰基、羟基、较低的酰基、羧基或类似物；R9为—C（O）—R10、-A1-C（O）—R10、—O-A2-C（O）—R10或四唑-5-基团，其表现出强效和选择性的β3肾上腺素能受体刺激活性。本发明还提供含有该化合物的药物组合物及其用途。
• Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
  申请人：Naganawa Atsushi

  公开号：US20070004716A1

  公开（公告）日：2007-01-04

  A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

  化合物的化学式为（I），其中公式中的符号与说明书中的含义相同，其盐、溶剂化物或前药具有DP受体结合和DP受体拮抗活性。因此，它可用于预防和/或治疗过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞病、伴随全身性肥大细胞激活的疾病、过敏性休克、支气管收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎和荨麻疹）、由于瘙痒行为（如搔抓和敲打）引起的炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等疾病的治疗。由于它特异性地结合于DP受体，并且弱地结合于其他前列腺素受体，因此可以作为副作用较小的药物。
• Compounds
  申请人：Alcaraz Lilian

  公开号：US20090298807A1

  公开（公告）日：2009-12-03

  The present invention relates to spirocyclic amide derivatives of the formula I, pharmaceutically acceptable salts thereof, a process for their preparation, pharmaceutical compositions containing them, and their use in therapy.

  本发明涉及公式 I 的螺环酰胺衍生物，其药学上可接受的盐，其制备方法，含有它们的制药组合物以及它们在治疗中的应用。
• 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE
  申请人：Nishi Tatsuya

  公开号：US20120245152A1

  公开（公告）日：2012-09-27

  A compound of the general formula (I): [wherein, R 1 represents a halogen atom, or the like, R 2 represents a hydrogen atom, or the like, R 3 and R 4 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, or the like, R 5 represents a hydrogen atom, a halogen atom, or the like, R 6 represents a hydrogen atom, a halogen atom, or the like, R 7 and R 8 , each independently, represent a hydrogen atom, a halogen atom, or the like, R 9 and R 10 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, R 11 and R 12 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, or the like, X represents an oxygen atom, a group —CH 2 —, or the like, Y represents a nitrogen atom, a group ═CH—, or the like, and Z represents a nitrogen atom, or the like] or a pharmacologically acceptable salt thereof, which has an excellent suppressive action on platelet aggregation, and is useful for prevention and/or treatment of thromboembolism.

  一种具有一般式（I）的化合物：[其中，R1代表卤素原子或类似物，R2代表氢原子或类似物，R3和R4各自独立地代表氢原子、C1-4烷基或类似物，R5代表氢原子、卤素原子或类似物，R6代表氢原子、卤素原子或类似物，R7和R8各自独立地代表氢原子、卤素原子或类似物，R9和R10各自独立地代表氢原子、C1-4烷基，R11和R12各自独立地代表氢原子、C1-4烷基或类似物，X代表氧原子、-CH2-基团或类似物，Y代表氮原子、═CH-基团或类似物，Z代表氮原子或类似物]或其药学上可接受的盐，具有出色的抑制血小板聚集作用，可用于预防和/或治疗血栓栓塞。